Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05899608 · ClinicalTrials.gov registry record · Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Summit Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,600
- Enrollment target
- 20
- Study locations
NCT05899608: Recruiting Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Summit Therapeutics.
NCT05899608 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Summit Therapeutics. The registered enrollment target is 1,600 participants, above the 649-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (147% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05899608, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Summit Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Primary Outcome
Overall Survival (OS) in the ITT population
Conditions Studied
Interventions
- BIOLOGICAL Ivonescimab Injection
- BIOLOGICAL Pembrolizumab Injection
Study Locations (20)
California
- LA Cancer Network - Anaheim
- The Oncology Institute of Hope & Innovation - Cerritos
- University of Southern California (USC) - Los Angeles
- Cedar Sinai Medical Center - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Sutter Institute for Medical Research - Sacramento
- UC Davis Medical Center - Sacramento
- University of California Los Angeles (UCLA) - Santa Monica
- Providence Medical Foundation - Santa Rosa
- Kaiser Permanente - Vallejo
Florida
- Florida Cancer Specialists & Research Institute (FCS)-East - Fort Myers
- BioResearch Partner- Hialeah Hospital - Hialeah
- Mayo Clinic - Jacksonville
Arizona
- Banner University Medical Center - Phoenix
- TMC Healthcare - Tucson
Colorado
- Rocky Mountain Cancer - Lone Tree
- Banner MD Anderson Cancer Center at North Colorado Medical Center - Loveland
Connecticut
- Hartford Hospital - Hartford
- Yale University - New Haven
Arkansas
- University of Arkansas - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 3 |
What NCT05899608 shows while recruiting
NCT05899608 is an interventional study that assigns participants to a tested intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 649-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (147% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ivonescimab Injection is the first listed.
NCT05899608 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05899608 about?
NCT05899608 is a clinical study titled "Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients". This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival asse...
What is the current status of trial NCT05899608?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,600 participants. The study started on 2023-10-26. Estimated completion is 2029-12-31.
What conditions does trial NCT05899608 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05899608?
The interventions under investigation include: Ivonescimab Injection (BIOLOGICAL), Pembrolizumab Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT05899608?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05899608 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05899608's enrollment target sits among peer trials
1,600 9th of 454 higher than 446 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI